(Hypertension. 2001;38:6.)
© 2001 American Heart Association, Inc.
Rapid Communications |
6-[18F]Fluorodopamine Positron Emission Tomographic (PET) Scanning for Diagnostic Localization of Pheochromocytoma
From the Pediatric and Reproductive Endocrinology Branch, National Institute of Child Health and Human Development (K.P.), Clinical Neurocardiology Section, National Institute of Neurological Disorders and Stroke (G.E., S.-T.L., D.S.G.), and Nuclear Medicine Department, Clinical Center (J.A.C., C.C.C.), National Institutes of Health, Bethesda, Md.
Correspondence to Dr Karel Pacak, PREB, NICHD, NIH, Building 10 Room 9D42, 10 Center Dr, Bethesda, MD 20892. E-mail karel{at}mail.nih.gov
Abstract
Abstract—— The diagnosis and treatment of pheochromocytoma depend critically on effective means to localize the tumor. Computed tomography and magnetic resonance imaging have good sensitivity but poor specificity for detecting pheochromocytoma, and nuclear imaging approaches such as 131I-metaiodobenzylguanidine scintigraphy have limited sensitivity. Here we report initial results using 6-[18F]fluorodopamine positron emission tomography (PET) scanning in the diagnostic localization of pheochromocytoma. Twenty-eight patients with known or clinically suspected pheochromocytoma underwent PET scanning after intravenous injection of 6-[18F]fluorodopamine. Of the 28 patients, 9 had surgical confirmation of the tumor, 8 had previously diagnosed metastatic pheochromocytoma, and 11 had plasma levels of metanephrines that were within normal limits. All 9 patients with surgically proven pheochromocytoma had abnormal 6-[18F]fluorodopamine PET scans that identified the tumors. All 8 patients with metastatic pheochromocytoma had extra-adrenal sites of 6-[18F]fluorodopamine-derived activity. Of the 11 patients with normal plasma levels of metanephrines, 9 had negative 6-[18F]fluorodopamine PET scans, 1 had extra-adrenal foci of 6-[18F]fluorodopamine-derived activity, and 1 had symmetric uptake of 6-[18F]fluorodopamine in the region of the adrenal glands. In patients with known disease, 6-[18F]fluorodopamine PET scanning can detect and localize pheochromocytomas with high sensitivity. In patients in whom the diagnosis of pheochromocytoma is considered but excluded because of negative plasma metanephrine results, 6-[18F]fluorodopamine PET scans are consistently negative. These findings justify a clinical trial of 6-[18F]fluorodopamine PET scanning as a diagnostic tool.
Key Words: fluorodopamine • pheochromocytoma • positron emission tomography • metanephrines
This article has been cited by other articles:
 |
|
 |
|
  H. P. H. Neumann and C. Eng The Approach to the Patient with Paraganglioma J. Clin. Endocrinol. Metab., August 1, 2009; 94(8): 2677 - 2683. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. J L M Timmers, A.-P. Gimenez-Roqueplo, M. Mannelli, and K. Pacak Clinical aspects of SDHx-related pheochromocytoma and paraganglioma Endocr. Relat. Cancer, June 1, 2009; 16(2): 391 - 400. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B Havekes, A A van der Klaauw, M M Weiss, J C Jansen, A G L van der Mey, A H J T Vriends, B A Bonsing, J A Romijn, and E P M Corssmit Pheochromocytomas and extra-adrenal paragangliomas detected by screening in patients with SDHD-associated head-and-neck paragangliomas Endocr. Relat. Cancer, June 1, 2009; 16(2): 527 - 536. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. S. GOLDSTEIN, Y. SHARABI, B. I. KARP, O. BENTHO, A. SALEEM, K. PACAK, and G. EISENHOFER Cardiac sympathetic denervation preceding motor signs in Parkinson disease* Cleveland Clinic Journal of Medicine, April 1, 2009; 76(Suppl_2): S47 - S50. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Kauhanen, M. Seppanen, J. Ovaska, H. Minn, J. Bergman, P. Korsoff, P. Salmela, J. Saltevo, T. Sane, M. Valimaki, et al. The clinical value of [18F]fluoro-dihydroxyphenylalanine positron emission tomography in primary diagnosis, staging, and restaging of neuroendocrine tumors Endocr. Relat. Cancer, March 1, 2009; 16(1): 255 - 265. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. Ilias, C. C. Chen, J. A. Carrasquillo, M. Whatley, A. Ling, I. Lazurova, K. T. Adams, S. Perera, and K. Pacak Comparison of 6-18F-Fluorodopamine PET with 123I-Metaiodobenzylguanidine and 111In-Pentetreotide Scintigraphy in Localization of Nonmetastatic and Metastatic Pheochromocytoma J. Nucl. Med., October 1, 2008; 49(10): 1613 - 1619. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Karagiannis, D. P Mikhailidis, V. G Athyros, and F. Harsoulis Pheochromocytoma: an update on genetics and management Endocr. Relat. Cancer, December 1, 2007; 14(4): 935 - 956. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. J.L.M. Timmers, J. A. Carrasquillo, M. Whatley, G. Eisenhofer, C. C. Chen, A. Ling, W. M. Linehan, P. A. Pinto, K. T. Adams, and K. Pacak Usefulness of Standardized Uptake Values for Distinguishing Adrenal Glands with Pheochromocytoma from Normal Adrenal Glands by Use of 6-18F-Fluorodopamine PET J. Nucl. Med., December 1, 2007; 48(12): 1940 - 1944. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I S Mackenzie, M Gurnell, K K Balan, H Simpson, K Chatterjee, and M J Brown The use of 18-fluoro-dihydroxyphenylalanine and 18-fluorodeoxyglucose positron emission tomography scanning in the assessment of metaiodobenzylguanidine-negative phaeochromocytoma Eur. J. Endocrinol., October 1, 2007; 157(4): 533 - 537. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. Ilias, A. Sahdev, R. H Reznek, A. B Grossman, and K. Pacak The optimal imaging of adrenal tumours: a comparison of different methods Endocr. Relat. Cancer, September 1, 2007; 14(3): 587 - 599. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Hadi, C. C. Chen, M. Whatley, K. Pacak, and J. A. Carrasquillo Brown Fat Imaging with 18F-6-Fluorodopamine PET/CT, 18F-FDG PET/CT, and 123I-MIBG SPECT: A Study of Patients Being Evaluated for Pheochromocytoma J. Nucl. Med., July 1, 2007; 48(7): 1077 - 1083. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. J.L.M. Timmers, A. Kozupa, C. C. Chen, J. A. Carrasquillo, A. Ling, G. Eisenhofer, K. T. Adams, D. Solis, J. W.M. Lenders, and K. Pacak Superiority of Fluorodeoxyglucose Positron Emission Tomography to Other Functional Imaging Techniques in the Evaluation of Metastatic SDHB-Associated Pheochromocytoma and Paraganglioma J. Clin. Oncol., June 1, 2007; 25(16): 2262 - 2269. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Kaji, J. A Carrasquillo, W M. Linehan, C. C Chen, G. Eisenhofer, P. A Pinto, E. W Lai, and K. Pacak The role of 6-[18F]fluorodopamine positron emission tomography in the localization of adrenal pheochromocytoma associated with von Hippel-Lindau syndrome Eur. J. Endocrinol., April 1, 2007; 156(4): 483 - 487. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Sullivan, T. Groshong, and J. D. Tobias Presenting Signs and Symptoms of Pheochromocytoma in Pediatric-aged Patients Clinical Pediatrics, October 1, 2005; 44(8): 715 - 719. [Abstract] [PDF]
|
|
|
|
 |
|
 H. P. H. Neumann, C. Pawlu, M. Peczkowska, B. Bausch, S. R. McWhinney, M. Muresan, M. Buchta, G. Franke, J. Klisch, T. A. Bley, et al. Distinct Clinical Features of Paraganglioma Syndromes Associated With SDHB and SDHD Gene Mutations JAMA, August 25, 2004; 292(8): 943 - 951. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Pacak, G. Eisenhofer, and D. S. Goldstein Functional Imaging of Endocrine Tumors: Role of Positron Emission Tomography Endocr. Rev., August 1, 2004; 25(4): 568 - 580. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. A. Eldadah, K. Pacak, G. Eisenhofer, C. Holmes, I. J. Kopin, and D. S. Goldstein Cardiac Uptake-1 Inhibition by High Circulating Norepinephrine Levels in Patients with Pheochromocytoma Hypertension, June 1, 2004; 43(6): 1227 - 1232. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Mansmann, J. Lau, E. Balk, M. Rothberg, Y. Miyachi, and S. R. Bornstein The Clinically Inapparent Adrenal Mass: Update in Diagnosis and Management Endocr. Rev., April 1, 2004; 25(2): 309 - 340. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. Ilias and K. Pacak Current Approaches and Recommended Algorithm for the Diagnostic Localization of Pheochromocytoma J. Clin. Endocrinol. Metab., February 1, 2004; 89(2): 479 - 491. [Full Text] [PDF]
|
|
|
|
 |
|
 C. Trampal, H. Engler, C. Juhlin, M. Bergstrom, and B. Langstrom Pheochromocytomas: Detection with 11C Hydroxyephedrine PET Radiology, February 1, 2004; 230(2): 423 - 428. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Mundschenk, N. Unger, S. Schulz, V. Hollt, S. Schulz, R. Steinke, and H. Lehnert Somatostatin Receptor Subtypes in Human Pheochromocytoma: Subcellular Expression Pattern and Functional Relevance for Octreotide Scintigraphy J. Clin. Endocrinol. Metab., November 1, 2003; 88(11): 5150 - 5157. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. M. Manger In Search of Pheochromocytomas J. Clin. Endocrinol. Metab., September 1, 2003; 88(9): 4080 - 4082. [Full Text] [PDF]
|
|
|
|
|
|
I. Ilias, J. Yu, J. A. Carrasquillo, C. C. Chen, G. Eisenhofer, M. Whatley, B. McElroy, and K. Pacak Superiority of 6-[18F]-Fluorodopamine Positron Emission Tomography Versus [131I]-Metaiodobenzylguanidine Scintigraphy in the Localization of Metastatic Pheochromocytoma J. Clin. Endocrinol. Metab., September 1, 2003; 88(9): 4083 - 4087. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. L. Bravo and R. Tagle Pheochromocytoma: State-of-the-Art and Future Prospects Endocr. Rev., August 1, 2003; 24(4): 539 - 553. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Gourgiotis, N. J. Sarlis, J. C. Reynolds, C. VanWaes, M. J. Merino, and K. Pacak Localization of Medullary Thyroid Carcinoma Metastasis in a Multiple Endocrine Neoplasia Type 2A Patient by 6-[18F]-Fluorodopamine Positron Emission Tomography J. Clin. Endocrinol. Metab., February 1, 2003; 88(2): 637 - 641. [Abstract] [Full Text] [PDF]
|
|